Skip to main content

Table 2 Potential use of miRNAs inEVs as cancer biomarkers

From: The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment

Cancer type Role miRNAs in EVs Source Isolation method Type assay Normalizing control Findings Refs.
Lung Diagnostic Screening model with miR-378a-3p, miR-379-5p, miR-139-5p and miR-200-5p Plasma ExoQuick qRT-PCR let-7a-5p Distiguishing between control and patients with any kind of nodules (NSCLC and lung granuloma), with AUC of 0.908 [92]
Diagnostic Diagnostic model with miR-151-5p, miR-30a-3p, miR-200b-5p, miR-629-5p, miR-100-5p and miR-154-3p Plasma ExoQuick qRT-PCR let-7a-5p Distiguishing between NSCLC and lung granuloma, with AUC of 0.76 [92]
Diagnostic Panel with let-7-5p, miR-21-5p, miR-24-3p and miR-486-5p Plasma Ultracentrifugation + immunoaffinity magnetic beads (anti EpCAM) RNA seq, qRT-PCR Cel-miR-39-3p Distiguishing NSCLC from symptomatic set, with AUC of 0.899 [93]
Diagnostic Panel with miR-181-5p, miR-30a-3p, miR-30e-3p and miR-361-5p Plasma Ultracentrifugation + immunoaffinity magnetic beads (anti EpCAM) RNA seq, qRT-PCR Cel-miR-39-3p Distinguishing adenocarcinoma from symptomatic set, with AUC of 0.936 [93]
Diagnostic Panel with miR-10b-5p, miR-15b-5p, and miR-320b Plasma Ultracentrifugation + immunoaffinity magnetic beads (anti EpCAM) RNA seq, qRT-PCR Cel-miR-39-3p Distinguishing SCC from symptomatic set, with AUC of 0.911 [93]
Prognostic miR-23b-3p, miR-10b-5p and miR-21-5p Plasma ExoQuick qRT-PCR, qRT-PCR let-7a-5p Associating with poor OS [94]
Prognostic miR-21-5p and miR-4257 Plasma Ultracentrifugation Microarray, qRT-PCR miR-16-5p Associating with poor DFS [95]
Colorectal Diagnostic let-7a-5p, miR-1229-3p, miR-1246, miR-150-5p, miR-21-5p, miR-223-3p and miR-23a-3p Serum Ultracentrifugation Microarray, RT-PCR miR-451a Comparing primary CRC with healthy control [98]
Diagnostic miR-125a-3p Plasma ExoQuick RNA seq, qRT-PCR miR-30e-5p Distinguishing CRC from control, with AUC of 0.6849. Combination of miR-125a-3p with CEA improve the AUC 0.855 [99]
Prognostic miR-19a-3p Serum Ultracentrifugation or Total Exosome Isolation Kit Microarray, qRT-PCR miR-16-5p Associating with poor OS and poor DFS [101]
Prognostic miR-4772-3p Serum ExoQuick RNA seq, qRT-PCR miR-16-5p Distinguishing recurrent CRC from non recurrent, with AUC of 0.72 [102]
Prostate Diagnostic miR-141-3p and miR-375 Serum ExoMir extraction kit Microarray, qRT-PCR Cel-miR-39-3p Comparing recurrent (metastatic) patients with non-recurrent patients [104]
Diagnostic miR-141-3p Serum ExoQuick qRT-PCR Cel-miR-39-3p Comparing PCa with BPH and control [107]
Diagnostic miR-21-5p, miR-375 and let-7c-5p Urine Ultracentrifugation qRT-PCR Cel-miR-39-3p Comparing Pca patients with healty controls AUCs: miR-21, 0.713; miR-375, 0.799; let-7c, 0.679 [111]
Prognostic Combination of miR-1290 and miR-375 Plasma ExoQuick RNA seq, qRT-PCR Genomic mean of miR-30a-5p and miR-30e-5p Associating with poor OS [112]
Breast Diagnostic miR-101-3p and miR-372-3p Serum ExoQuick qRT-PCR Mean value of miR-16-5p and miR-484 Comparing invasive breast cancer patients with healthy control [117]
Diagnostic Combination of miR-1246 and miR-21-5p Plasma Ultracentrifugation or ExoQuick RNA seq, qRT-PCR Cel-miR-54-3p Distinguishing breast cancer patients with healthy control, with AUC of 0.7266 [118]
Ovarian Diagnostic miR-373-3p, miR-200a-3p, miR-200b-3p and miR-200c-3p Serum Total exosome isolation reagent qRT-PCR miR-484 Comparing EOC with healthy control [120]
Prognostic miR-200a-3p, miR-200b-3p and miR-200c-3p Serum Total exosome isolation reagent qRT-PCR miR-484 Associating with advanced FIGO stage and lymph node metastasis [120]
Melanoma Diagnostic miR-125-5p Serum ExoQuick qRT-PCR miR-16-5p Comparing metastaitic melanoma patients with disease free patients with melanoma and helthy conrtols [125]
Diagnostic miR-17-5p, miR-19a-3p, miR-21-5p, miR-126-3p, miR-149-5p Plasma ExoQuick Microarray, qRT-PCR Cel-miR-39-3p Comparing metastatic melanoma patients with healthy controls [128]